Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy

Table 4

Neonatal outcomes of pregnant women using insulin glargine versus NPH among the studies selected for meta-analysis.

Neonatal outcome	Number of; studies	Insulin glargine		NPH		Mean Difference*/; odds ratio**	95% confidence limits
		Unadjusted mean/events	Number of; patients	Unadjusted mean/events	Number of; patients		Lower limit	Upper limit
Gestational age at delivery (wks)	7	37.3	289	37	322	0.09*	−0.43	0.61
Birth weight (g)	7	3463	288	3412	313	12.97*	−19.18	45.12
NICU admissions (𝑛)	6	94	274	94	307	0.79**	0.45	1.38
Apgar score—5 minute (<7, 𝑛)	4	6	149	4	183	1.36**	0.26	7.06
Macrosomia (>4000 g, 𝑛)	4	37	157	39	198	1.20**	0.71	2.02
LGA (>90th percentile, 𝑛)	4	58	165	75	216	1.05**	0.68	1.63
Congenital malformations (𝑛)	5	17	237	23	271	0.78**	0.39	1.59
Respiratory distress syndrome (𝑛)	6	24	261	15	288	1.62**	0.82	3.21
Neonatal hypoglycemia (𝑛)	7	58	304	62	346	0.99**	0.63	1.56
Hyperbilirubinemia (𝑛)	6	58	272	60	314	0.93**	0.49	1.79

*Mean difference: insulin glargine versus NPH insulin; **Odds ratio: insulin glargine/NPH insulin.